BMS will co-develop and co-commercialize BioNTech’s bispecific antibody BNT327 for solid tumors in a deal worth up to $11.1B ...

BioNTech SE's $11.1B oncology move signals potential, but clinical hurdles remain. Click for my look at the BNTX deal with ...

Bristol-Myers Squibb and BioNTech announced a major deal worth up to $11 billion in early June. Click here to find out why I ...

BioNTech and Bristol Myers Squibb have agreed to jointly develop and commercialize BioNTech’s BNT327 cancer-drug candidate in ...

Marketed as BNT327, the PD-L1xVEGF-A bispecific antibody has the potential to become what the involved parties believe is a ...

U.S.-listed shares of BioNTech jumped more than 15% Monday morning after the German vaccine maker announced a collaboration ...

A new multinational study analyzing data from over 230 million people across 20 global sites highlights the relationship ...

A recent study by Kearney revealed that 68% of global industry leaders in the healthcare sector see AI and advanced analytics as major value drivers. All attention at the moment is on BioNTech’s ...

Last Friday, Summit announced preliminary results from a Phase 3 study ... in a research note that more than bringing its cancer drugs for potential combinations, the BMS brings to BioNTech ...

The oncology giant will pay $1.5 billion to co-develop a BioNTech drug that targets the proteins PD-L1 and VEGF, following ...

See Also: Using Weed While Pregnant: Study Of 500k People Reveals ... aiding scientists in disease research. On the other hand, BioNTech has faced financial challenges, reporting deeper losses ...